Search research articles
Contact Us
Filters
Showing results (91-100 of 108) with videos related to
Page
of 11
Sort By:
Blood Cancer Journal
|
February 25, 2022
Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies
Adam D Cohen, Samir Parekh, Bianca D Santomasso, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
June 27, 2020
Summary of the 2019 Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling
Sarah A Holstein, Alan Howard, David Avigan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 3, 2025
Long-Term (≥5-Year) Remission and Survival After Treatment With Ciltacabtagene Autoleucel in CARTITUDE-1 Patients With Relapsed/Refractory Multiple Myeloma
Sundar Jagannath, Thomas G Martin, Yi Lin, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
May 20, 2026
Non-ICANS Neurologic Events in Patients With Relapsed/Refractory Multiple Myeloma Treated With Ciltacabtagene Autoleucel: Clinical Presentation and Management in CARTITUDE Studies
Paula Rodríguez-Otero, Jaime Gállego Pérez-Larraya, Yi Lin, et al.
Leukemia
|
January 27, 2025
International myeloma working group immunotherapy committee recommendation on sequencing immunotherapy for treatment of multiple myeloma
Luciano J Costa, Rahul Banerjee, Hira Mian, et al.
JCI Insight
|
March 5, 2019
Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma
Alfred L Garfall, Edward A Stadtmauer, Wei-Ting Hwang, et al.
JCI Insight
|
April 20, 2018
Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma
Alfred L Garfall, Edward A Stadtmauer, Wei-Ting Hwang, et al.
The Lancet. Haematology
|
February 3, 2022
Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group
Noopur S Raje, Elias Anaissie, Shaji K Kumar, et al.
The Lancet. Oncology
|
December 21, 2019
Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study
Sagar Lonial, Hans C Lee, Ashraf Badros, et al.
Lancet (London, England)
|
June 27, 2021
Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study
Jesus G Berdeja, Deepu Madduri, Saad Z Usmani, et al.
Page
of 11
Search research articles
Search
Showing results (91-100 of 108) with videos related to
Sort By:
Page
of 11
Blood Cancer Journal
|
February 25, 2022
Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies
Adam D Cohen, Samir Parekh, Bianca D Santomasso, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
June 27, 2020
Summary of the 2019 Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling
Sarah A Holstein, Alan Howard, David Avigan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 3, 2025
Long-Term (≥5-Year) Remission and Survival After Treatment With Ciltacabtagene Autoleucel in CARTITUDE-1 Patients With Relapsed/Refractory Multiple Myeloma
Sundar Jagannath, Thomas G Martin, Yi Lin, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
May 20, 2026
Non-ICANS Neurologic Events in Patients With Relapsed/Refractory Multiple Myeloma Treated With Ciltacabtagene Autoleucel: Clinical Presentation and Management in CARTITUDE Studies
Paula Rodríguez-Otero, Jaime Gállego Pérez-Larraya, Yi Lin, et al.
Leukemia
|
January 27, 2025
International myeloma working group immunotherapy committee recommendation on sequencing immunotherapy for treatment of multiple myeloma
Luciano J Costa, Rahul Banerjee, Hira Mian, et al.
JCI Insight
|
March 5, 2019
Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma
Alfred L Garfall, Edward A Stadtmauer, Wei-Ting Hwang, et al.
JCI Insight
|
April 20, 2018
Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma
Alfred L Garfall, Edward A Stadtmauer, Wei-Ting Hwang, et al.
The Lancet. Haematology
|
February 3, 2022
Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group
Noopur S Raje, Elias Anaissie, Shaji K Kumar, et al.
The Lancet. Oncology
|
December 21, 2019
Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study
Sagar Lonial, Hans C Lee, Ashraf Badros, et al.
Lancet (London, England)
|
June 27, 2021
Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study
Jesus G Berdeja, Deepu Madduri, Saad Z Usmani, et al.
Page
of 11